

Characteristics of COVID-19 patients dying in Italy Report based on available data on April 6th , 2020

1. Sample

The present report describes characteristics of 14,860 COVID-19 patients dying in Italy.* Geographic distribution across the 19 regions and 2 autonomous provinces of Trento and Bozen is presented in the table below. Data are update to April 2nd, 2020.

Tabel 1. Geographic distribution of	f deceased	natients COVID-2019 nositive
Tuber 1. Geographic distribution of	juccuscu	putients covid zors positive

REGION	Ν	%	
Lombardia	8,915	60.0	
Emilia-Romagna	2,038	13.7	
Piemonte	961	6.5	
Veneto	668	4.5	
Liguria	460	3.1	
Marche	278	1.9	
Toscana	220	1.5	
Trento	217	1.5	
Lazio	209	1.4	
Puglia	186	1.3	
Bolzano	163	1.1	
Friuli-Venezia Giulia	151	1.0	
Campania	87	0.6	
Sicilia	67	0.5	
Valle d'Aosta	56	0.4	
Umbria	44	0.3	
Sardegna	41	0.3	
Calabria	40	0.3	
Abruzzo	33	0.2	
Basilicata	14	0.1	
Molise	12 0.1		
Total	14,860	100.0	

* COVID-19 related deaths presented in this report are those occurring in patients who test positive for SARSCoV-2 RT by PCR, independently from pre-existing diseases.

2. Demographics

Mean age of patients dying for COVID-2019 infection was 78 (median 80, range 5-100, IQR 73 -85). Women were 4,798 (32.3%). *Figure 1* shows that median age of patients dying for COVID-2019 infection was more than 15 years higher as compared with the national sample diagnosed with COVID-2019 infection (median age 62 years). *Figure 2* shows the absolute number of deaths by age group. Women dying for COVID-2019 infection had an older age than men (median age women 82 - median age men 78).





Figure 1. Median age of patients with COVID-2019 infection and COVID-19 positive deceased patients

Figure 2. Absolute number of deaths by age group



Note: For 1 deceased person age was not possible to be evaluated

3. Pre-existing conditions

Table 1 presents most common comorbidities diagnosed before COVID-2019 infection. Data on diseases were based on chart review and was available on 1,290 patients dying in-hospital for whom it was possible to analyse clinic charts. Mean number of diseases was 3.3 (median 3, SD 1.9). Overall, 3.3% of the sample presented with a no comorbidities, 14.4% with a single comorbidity, 20.5% with 2, and 61.9% with 3 or more.

Before hospitalization, 26% of COVID-19 positive deceased patients followed ACE-inhibitor therapy and 16% angiotensin receptor blockers-ARBs therapy. This information can be underestimated because data on drug treatment before admission were not always described in the chart.

Diseases	N	%
Ischemic heart disease	363	28.1
Atrial Fibrillation	290	22.5
Heart failure	207	16.0
Stroke	144	11.2
Hypertension	911	70.6
Type 2-Diabetes	409	31.7
Dementia	203	15.7
COPD	234	18.1
Active cancer in the past 5 years	217	16.8
Chronic liver disease	49	3.8
Chronic renal failure	298	23.1
ніv	1	0.1
Autoimmune diseases	40	3.1
Obesity	129	10.0
Number of comorbidities		
0 comorbidities	42	3.3
1 comorbidity	186	14.4
2 comorbidities	264	20.5
3 comorbidities and over	798	61.9

 Table 1. Most common comorbidities observed in COVID-19 positive deceased patients

Table 3 presents the most common pre-existing chronic pathologies in patients who died, separately in men (n = 894) and women (n = 396). The average number of pathologies observed in women is 3.3 (median 3, Standard Deviation 1.9). In men the average number of pathologies observed is 3.3 (median 3, Standard Deviation 1.9).

Tabella 3. Most common comorbidities observed in COVID-19 positive deceased patients by gender

Diseases	N	%		N	%
Ischemic heart disease	78	19.7		285	31.9
Atrial Fibrillation	93	23.5		197	22.0
Heart Failure	85	20.6		122	13.4
Stroke	41	10.4		103	11.5
Hypertension	296	74.7		615	68.8
Type 2-Diabetes	115	29.0	1	294	32.9
Dementia	82	20.7		121	13.5
COPD	52	13.1		182	20.4
Active cancer in the past 5 years	63	15.9	1	154	17.2
Chronic liver disease	10	2.5		39	4.4
Chronic renal failure	75	18.9		223	24.9
HIV	0	0.0		1	0.1
Autoimmune diseases	20	5.1		20	2.2
Obesity	48	12.1		81	9.1
Number of comorbidities					
0 comorbidities	7	1.8		35	3.9
1 comorbidity	55	13.9		131	14.7
2 comorbidities	85	21.5		179	20.0
3 comorbidities and over	249	62.9		549	61.4

Women

Men

4. Diagnosis of hospitalization

In 93.5% of hospitalizations, conditions (e.g. pneumonia, respiratory failure) or symptoms (e.g. fever, dyspnoea, cough) compatible with COVID-19 were mentioned. In 81 cases (6.5% of cases) the diagnosis of hospitalization was not related to the infection. In 7 cases the diagnosis of hospitalization concerned exclusively neoplastic pathologies, in 38 cases cardiovascular pathologies (for example IMA, heart failure, stroke), in 12 cases gastrointestinal pathologies (for example cholecystitis, perforation of the intestine, intestinal obstruction, cirrhosis), in 24 cases other pathologies.

5. Symptoms

Figure 3 shows symptoms most commonly observed at hospital admission. Fever, dyspnoea and cough were the most commonly observed symptoms, while diarrhoea and haemoptysis were less commonly observed. Overall, 5.5% of patients did not present any symptoms at hospital admission.




Figure 3. Most common symptoms observed in COVID-19 positive deceased patients

6. Acute conditions

Acute Respiratory Distress syndrome was observed in the majority of patients (96.5% of cases), followed by acute renal failure (24.3%). Superinfection was observed in 10.2% and acute cardiac injury in 9.8% of cases.

7. Treatments


Antibiotics were used by 84% of patients during hospital stay, while less used were antivirals (55%) and corticosteroids (34%). Concomitant use of these 3 treatments was observed in 18.8% of cases.

Out of COVID-19 positive deceased patients, 2.4% were treated with Tocilizumab during hospitalization.

8. Time-line

Figure 4 shows, for COVID-19 positive deceased patients, the median times, in days, from the onset of symptoms to death (10 days), from the onset of symptoms to hospitalization (5 days) and from hospitalization to death (5 days). The time from hospitalization to death was 3 days longer in those who were transferred to intensive care than those who were not transferred (7 days vs. 4 days).

Figure 4. Median hospitalization times (in days) in COVID-19 positive deceased patients



9. Deaths under the age of 50 years

As of April 6th, 178 out of the 14,860 (1.2%) positive COVID-19 patients under the age of 50 died. In particular, 42 of these were less than 40 years, 28 men and 14 women (age range between 5 and 39 years). For 6 patients under the age of 40 years no clinical information is available; the remaining 28 had serious pre-existing pathologies (cardiovascular, renal, psychiatric pathologies, diabetes, obesity) and 8 had no major pathologies.

This report was produced by COVID-19 Surveillance Group

Members of the COVID-19 Surveillance Group

Luigi Palmieri, Xanthi Andrianou, Pierfrancesco Barbariol, Antonino Bella, Stefania Bellino, Eva Benelli, Luigi Bertinato, Stefano Boros, Gianfranco Brambilla, Giovanni Calcagnini, Marco Canevelli, Maria Rita Castrucci, Federica Censi, Alessandra Ciervo, Elisa Colaizzo, Fortunato D'Ancona, Martina Del Manso, Chiara Donfrancesco, Massimo Fabiani, Antonietta Filia, Marco Floridia, Marina Giuliano, Tiziana Grisetti, Martin Langer, Ilaria Lega, Cinzia Lo Noce, Pietro Maiozzi, Fiorella Malchiodi Albedi, Valerio Manno, Margherita Martini, Alberto Mateo Urdiales, Eugenio Mattei, Claudia Meduri, Paola Meli, Giada Minelli, Manuela Nebuloni, Lorenza Nisticò, Marino Nonis, Graziano Onder, Lucia Palmisano, Nicola Petrosillo, Patrizio Pezzotti, Flavia Pricci, Ornella Punzo, Vincenzo Puro, Valeria Raparelli, Giovanni Rezza, Flavia Riccardo, Maria Cristina Rota, Paolo Salerno, Debora Serra, Andrea Siddu, Paola Stefanelli, Manuela Tamburo De Bella, Dorina Tiple, Brigid Unim, Luana Vaianella, Nicola Vanacore, Monica Vichi, Emanuele Rocco Villani, Silvio Brusaferro.